Inclusion and diversity in clinical trials: Actionable steps to drive lasting change

Background: Improving diversity in clinical trials is essential in order to produce generalizable results. Although the importance of representation has become increasingly recognized, identifying strategies to approach this work remains elusive. This article reviews the proceedings of a multi-stakeholder conference about the current state of diversity in clinical trials and outlines actionable steps for improvement.Methods: Conference attendees included representatives from the United States Food and Drug Administration (FDA), National Institutes of Health (NIH), practicing clinical investigators, pharmaceutical and device companies, community-based organizations, data analytics companies, and patient advocacy groups. At this virtual event, attendees were asked to consider key questions around best practices for engagement of underrepresented populations.Results: Community engagement is an integral part of recruitment and retention of underrepresented groups. Decentralization of sites and use of digital tools can enhance the accessibility of clinical research. Finally, improving representation among investigators and clinical research staff may translate to diverse clinical trial participants.Conclusion: Improving diversity in clinical trials is an ethical and scientific imperative, which requires a multifaceted approach.

Automated summary

This article reviews the proceedings of a conference on diversity in clinical trials, outlining actionable steps for improvement. It emphasizes the importance of community engagement, decentralization of sites, use of digital tools, and increasing representation among investigators and clinical research staff in order to improve diversity in clinical trials.